Core Viewpoint - The company, He Bo Pharmaceutical-B (02142.HK), has announced a placement agreement with Citibank to issue 45.022 million shares at a price of HKD 11.50 per share, which represents approximately 5.45% of the existing issued share capital [1] Group 1 - The placement shares will account for approximately 5.17% of the enlarged issued share capital post-placement, assuming full subscription and no changes in the issued share capital from the announcement date to completion [1] - The estimated total gross proceeds from the placement are approximately HKD 517.8 million, with net proceeds expected to be around HKD 511.7 million after deducting placement commissions and other related expenses [1] Group 2 - The net proceeds from the placement will be allocated as follows: approximately 50% for the development of innovative drug assets, about 40% for advancing clinical trials of existing pipeline drug assets, and around 10% for working capital and other general corporate purposes [1]

智通财经APP讯，和铂医药-B(02142)公布，于2025年8月29日，该公司与配售代理订立配售协议，据 此，公司有条件同意透过配售代理以每股配售股份11.50港元的价格向不少于六名承配人配售合共4502.2 万股配售股份。每股配售股份11.50港元，较股份在2025年8月28日收市价每股股份12.70港元折让约 9.45%。 假设全部4502.2万股配售股份获悉数认购，净筹约5.117亿港元。约50%将用于开拓创新药物资产的研 发，约40%将用于推进现有管线药物资产的临床试验，约10%将用于营运资金及其他一般企业用途。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告或其任何文本概不得直接或間接在美國，或在發放或派發本公告屬違法的任何其他司法 權區內發放或派發。 本公告並不構成在美國購買或認購證券的任何要約或招攬，亦不構成其任何一部分。本公告提 及的證券並無且將不會根據《1933年美國證券法》（「美國證券法」）登記，且不得在美國提呈發 售或出售，惟根據美國證券法的規定進行登記，或適用豁免登記，或進行毋須遵守有關登記規 定的交易則除外。本公司無意按照美國證券法於美國登記本公告所述任何證券，亦無意於美國 公開發售證券。 配售須待聯交所上市委員會批准配售股份上市及買賣（且有關上市及批准其後並 未於配售完成前遭撤回）後，方可作實。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 根據一般授權配售新股 獨家整體協調人及獨家配售代理 ...

Summary of the Conference Call for Heptagon Pharmaceuticals Company Overview - Heptagon Pharmaceuticals is leveraging the Nona Biotech platform, innovative capabilities in the Chinese and Asian capital markets, and an expanded clinical pipeline to build a sustainable value growth system [2][3]. Key Industry and Company Insights Strategic Collaborations - Heptagon Pharmaceuticals has established a global strategic partnership with AstraZeneca worth $4.6 billion, and a collaboration with Otsuka Pharmaceutical for BCMA CD3 bispecific antibodies valued at approximately $700 million [2][6]. - The company has also formed ongoing technical collaborations with Bistera in the TCE muscle cell connector field, contributing to stable revenue streams [2][6]. Financial Performance - In the first half of 2025, Heptagon Pharmaceuticals reported revenue of $101 million, a year-on-year increase of 327%, with molecular licensing fees growing by 350% [4][30]. - The net profit for the same period was approximately $73 million, reflecting a nearly 51-fold increase compared to the previous year [4][30]. Clinical Pipeline Developments - The HOBM9,378 project, a long-acting fully human TSLP, has entered global validation clinical stages, with a $1 billion overseas licensing agreement with Winward Bio for the COPD market [2][7]. - The new generation immune-suppressive regulatory T cell-targeting molecule HBM4,003 is advancing in Phase II trials for NSCLC, with clinical data expected to be reported at ESMO [2][8]. Technological Advancements - The Nona Biotech platform has seen explosive growth, with a 165% year-on-year increase in routine platform research and technology licensing, and over 100 partners engaged in more than 300 projects [5][29]. - The Humetrics AI platform has been developed to guide antibody discovery and optimize drug design, enhancing innovation capabilities [4][29]. Market Position and Future Outlook - Heptagon Pharmaceuticals has established itself as a leader in the antibody field, with over $2 billion in external collaborations, particularly excelling in bispecific antibodies [4][9]. - The company is focusing on autoimmune diseases, with significant market potential projected to reach $55.6 billion globally by 2024 [17][18]. Additional Important Insights Cash Reserves and Financial Health - As of June 30, 2025, the company had cash reserves of approximately $320 million, with operating cash flow increasing by 47% year-on-year [34][35]. - The net assets stood at $280 million, a 129% increase from the previous year-end, indicating a robust financial structure [35]. Future Catalysts - Upcoming clinical trials include the launch of HOBM9,378 in global Phase II trials and multiple new clinical applications expected to be submitted within the next 12 months [37][39]. Strategic Vision - Heptagon Pharmaceuticals aims to maximize value through strategic partnerships and innovative technology platforms, focusing on complex molecules and expanding into new therapeutic areas [44][57]. AI Integration - The integration of AI technology is expected to enhance drug discovery and development efficiency, with applications in clinical data analysis and biomarker research [59][60]. This summary encapsulates the key points from the conference call, highlighting Heptagon Pharmaceuticals' strategic initiatives, financial performance, clinical advancements, and future outlook in the biopharmaceutical industry.

Core Viewpoint - Heptagon Pharmaceuticals (02142.HK) has achieved significant performance growth through continuous business development (BD) collaborations and the release of its underlying technology platform value, positioning itself as a key player in the global antibody drug development landscape [1][12]. Financial Performance - In the first half of 2025, Heptagon Pharmaceuticals reported total revenue of 725 million yuan and a net profit of approximately 523 million yuan, marking a 51-fold increase compared to the same period in 2024, significantly surpassing the full-year profit of 20 million yuan in 2024 [1]. - The company has established over 40 collaborations, with a total potential cooperation amount exceeding 10 billion USD [1]. Business Development Strategy - The BD income has transitioned from being an "occasional event" to a "normal cash flow," becoming a core pillar supporting the company's profitability since 2023 [3]. - In the first half of 2025, Heptagon Pharmaceuticals accelerated its BD activities, achieving four collaborations with various partners, including AstraZeneca and Otsuka Pharmaceutical, validating the stability and sustainability of BD income [3][4]. Technological Advancements - Heptagon Pharmaceuticals' core competitive advantage lies in its globally unique patented fully human only heavy chain antibody development platform, HCAb Harbour Mice®, which has been continuously upgraded to support its BD strategy [1][9]. - The company has developed multiple advanced technology platforms, including HBICE®, HBICATM, ADC2.0, and Hu-mAtrlxTM, enhancing its product competitiveness [7][8]. Product Pipeline and Market Position - The company is advancing several key candidate drugs, with the first product, HBM9161, entering the final stages of commercialization, expected to be the first commercialized product in China for treating generalized myasthenia gravis [10]. - Heptagon Pharmaceuticals aims to transition from a traditional technology supplier to a strategic partner in the global pharmaceutical industry, enhancing its role in the global antibody drug development ecosystem [12][13]. Future Outlook - By 2025, Heptagon Pharmaceuticals aims to enter the "3.0 phase," focusing on building a global collaborative ecosystem and maximizing product value through clinical pipeline expansion [12]. - The company has reported a cash reserve of 2.291 billion yuan as of June 2025, a 92% increase from the previous year, providing ample resources for technology iteration and pipeline advancement [12].

Core Viewpoint - The company, Heptagon Pharmaceuticals (和铂医药-B), experienced a significant stock price increase following the announcement of its interim financial results, reflecting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from licensing fees increased from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new product licenses [1] - Research services and technology licensing revenue rose by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - In March 2025, the company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation bispecific antibodies targeting immune diseases, tumors, and other conditions [1] - The collaboration includes the use of Heptagon's proprietary fully human antibody technology platform, Harbour Mice, for multiple projects across various therapeutic areas [1] - As part of this agreement, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), experienced a significant stock price increase following the release of its interim financial results, highlighting strong revenue growth and strategic partnerships [1] Financial Performance - The company reported revenue of approximately $101 million, representing a year-on-year increase of about 327% [1] - Net profit for the period was $72.99 million, showing a remarkable year-on-year growth of 5,125% [1] - Revenue from molecular licensing fees rose from $20.8 million to $93.7 million, primarily due to strategic collaborations with global pharmaceutical companies and new licensing agreements for innovative products [1] - Research services and technology licensing fee income increased by 164.9%, from $2.9 million to $7.6 million [1] Strategic Partnerships - The company entered into a global strategic collaboration with AstraZeneca to co-develop next-generation multispecific antibodies targeting immune diseases, tumors, and other conditions, set to commence in March 2025 [1] - The collaboration includes the use of the company's proprietary fully human antibody technology platform, Harbour Mice, across multiple therapeutic areas [1] - In return for this partnership, the company is set to receive up to approximately $4.6 billion in upfront and milestone payments, along with tiered royalties based on net sales [1]

Core Viewpoint - Heptagon Pharmaceuticals reported a significant increase in revenue and profit for the first half of 2025, showcasing strong growth driven by innovative product licensing and collaborations [2] Financial Performance - Total revenue for the first half of 2025 reached approximately 725 million yuan, representing a year-on-year growth of 327% [2] - The company's profit amounted to about 523 million yuan, reflecting a staggering year-on-year increase of 51 times [2] - Cash reserves stood at approximately 2.291 billion yuan, up 92% from the end of the previous year [2] Strategic Collaborations - In March 2025, Heptagon Pharmaceuticals entered a global strategic partnership with AstraZeneca to co-develop next-generation multi-specific antibody therapies for various diseases [3] - The collaboration includes licensing agreements based on Heptagon's proprietary Harbour Mice fully human antibody technology across multiple therapeutic areas [3] - Heptagon also signed several licensing agreements with global partners during the reporting period, including a deal with Windward Bio for HBM9378/SKB378 and a global strategic cooperation with Otsuka Pharmaceutical for HBM7020 [3] Innovation and Future Plans - Heptagon Pharmaceuticals focuses on developing innovative therapies for immune diseases and tumors, leveraging its core technological advantages and differentiated product pipeline [4] - The company aims to accelerate the development of new biological therapies targeting both new and known targets, with multiple clinical trials planned for products like HBM4003, HBM9378, and HBM1020 [4] - Heptagon plans to expand its platform capabilities into the immune and inflammatory fields, utilizing its Harbour Mice and HBICE drug discovery engines to identify new high-quality candidate molecules [4]

和铂医药(2142.HK)公布业绩显示，2025年上半年总收入约7.25亿元人民币（约1.01亿美元），同比增长 327%；盈利约5.23亿元人民币（约7300万美元），同比增长51倍；现金储备充盈，约合 22.91亿元人民 币（约3.2 亿美元），较去年年底增长92%。 和铂医药创始人、董事长兼首席执行官王劲松博士表示："2025年上半年，和铂医药实现了多项重大里 程碑进展。公司盈利同比增长超50倍，展现出强劲的增长态势。其中，基于创新产品的对外授权与合 作，为公司的收入增长做出了重要贡献，并逐步成为公司的常态化收入来源。这充分验证了公司将创新 能力转化为商业价值的可持续性，同时也体现了我们涵盖战略合作、授权合作、平台合作、创新孵化等 多元化业务模式的成功实践。依托行业领先的Harbour Mice?技术平台及由其延展的2.0版本技术平台体 系，和铂医药已建立了强大的全球合作生态，成为全球抗体药物开发的'新基建'。未来，和铂医药将持 续深化源头创新，加速助力新一代生物疗法研发，为全球患者带来更优质的治疗方案。" ...

和铂医药创始人、董事长兼首席执行官王劲松博士表示："2025年上半年，和铂医药实现了多项重大里 程碑进展。公司盈利同比增长超50倍，展现出强劲的增长态势。其中，基于创新产品的对外授权与合 作，为公司的收入增长做出了重要贡献，并逐步成为公司的常态化收入来源。这充分验证了公司将创新 能力转化为商业价值的可持续性，同时也体现了我们涵盖战略合作、授权合作、平台合作、创新孵化等 多元化业务模式的成功实践。依托行业领先的Harbour Mice®技术平台及由其延展的2.0版本技术平台体 系，和铂医药已建立了强大的全球合作生态，成为全球抗体药物开发的'新基建'。未来，和铂医药将持 续深化源头创新，加速助力新一代生物疗法研发，为全球患者带来更优质的治疗方案。" 和铂医药(2142.HK)公布业绩显示，2025年上半年总收入约7.25亿元人民币（约1.01亿美元），同比增长 327%；盈利约5.23亿元人民币（约7300万美元），同比增长51倍；现金储备充盈，约合22.91亿元人民 币（约3.2 亿美元），较去年年底增长92%。 ...